Cutaneous T-cell Lymphoma (CTCL) Market to Show Positive Growth as Key Players Such as Pfizer, Eisai, Citius Pharmaceuticals, Bristol Myers Squibb, Merck, and others are Developing Novel Therapies, Assesses DelveInsight

News provided by

Sep 07, 2022, 11:30 ET

The emerging drugs shall significantly impact the cutaneous T-cell lymphoma (CTCL) market size, considering the robust pipeline with a large variety of therapeutic classes in the periphery. Presently, many biologics and drugs are under investigation for CTCL treatment. Key players such as Soligenix, Eisai, Merck Sharp & Dohme, Innate Pharma, 4SC AG, Beigene, and others will boost the cutaneous T-cell lymphoma market dynamics in the coming years.

LAS VEGAS, Sept. 7, 2022 /PRNewswire/ -- DelveInsight's Cutaneous T-cell Lymphoma (CTCL) Market Insights report includes a comprehensive understanding of current treatment practices, cutaneous T-cell lymphoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan].

Key Takeaways from the Cutaneous T-cell Lymphoma Market Report

As per DelveInsight analysis, the cutaneous T-cell lymphoma market size in the 7MM was valued at approximately USD 399 million in 2021.
As per the estimates, the total cutaneous T-cell lymphoma incident population in the 7MM was around 7,485 in 2021.
Leading cutaneous T-cell lymphoma companies such as Pfizer, Eisai, Citius Pharmaceuticals, Bristol Myers Squibb, Merck, Kyowa Kirin, Medivir, Seagen, Soligenix, 4SC AG, Galderma, Equillium, Innate Pharma, BeiGene, Codiak BioSciences, Astex Pharmaceuticals, and others are developing novel cutaneous T-cell lymphoma drugs that can be available in the cutaneous T-cell lymphoma market in the upcoming years.
The cutaneous T-cell lymphoma therapies in the pipeline include SGX301, Pembrolizumab, Resminostat, CD11301, EQ101, Tolinapant (ASTX660), exoIL-12, Lacutamab, Remetinostat, Resminostat, Tislelizumab (BGB-A317), and others.
Compared to other indications, CTCL has a good prognosis, which prevents treatment-related toxicity. There are many established patient advocacy groups and international collaborations for this indication.

Discover which therapies are expected to grab major cutaneous T-cell lymphoma market share @Cutaneous T-cell Lymphoma Market Report

Cutaneous T-cell Lymphoma Overview

Cutaneous T-cell lymphoma (CTCL) is a group of diseases characterized by an abnormal accumulation of malignant T-cells in the skin, which can lead to the formation of rashes, plaques, and tumors. Furthermore, CTCLs account for more than three out of every four skin lymphomas diagnosed, and they frequently manifest as eczema-like skin rashes and can affect multiple body parts. The exact cutaneous T-cell lymphoma causes are still not known.

Cutaneous T-cell lymphoma symptoms include skin patches and lumps, enlarged lymph nodes, hair loss, thickening of the skin on the palms of the hands and soles of the feet, and rash-like skin redness that is intensely itchy all over the body.

A thorough clinical evaluation, detection of specific CTCL symptoms and physical findings, a detailed patient history, and a variety of specialized tests are used for cutaneous T-cell lymphoma diagnosis.

Cutaneous T-cell Lymphoma Epidemiology Segmentation

As per our analysis, there were around 7,485 cutaneous T-cell lymphoma incident cases in the 7MM in 2021.

Among the EU5 countries, Germany had the highest incidence of CTCL in 2021.

The cutaneous T-cell lymphoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Incident Population of CTCL
Type-specific Cases of CTCL
Sub-type specific incidence of CTCL
Gender-specific cases of CTCL
Stage-specific cases of CTCL
Treatment-eligible incident population in early-and advanced-stage

Download the report to understand which factors are driving CTCL epidemiology trends @Cutaneous T-cell Lymphoma Epidemiological Insights

Cutaneous T-cell Lymphoma Treatment Market

A patient's CTCL treatment plan is determined by several factors, including the person's overall health, age, and disease stage. The type and extent of skin lesions (patches, plaques, or tumors), the number of Sézary cells in the blood, and transformation to large cell type or folliculotropic cancer (involving the hair follicles) all influence cutaneous T-cell lymphoma treatment options.

Patients with early-stage mycosis fungoides or Sézary syndrome may respond well to skin-directed therapies alone. In contrast, patients with advanced disease may require a combination of topical and systemic therapies (affecting the entire body). ISTODAX (romidepsin), VALCHLOR (mechlorethamine), UVADEX (methoxsalen), TARGRETIN (bexarotene), ADCETRIS (brentuximab vedotin), POTELIGEO (mogamulizumab), and ZOLINZA (vorinostat) are some of the FDA-approved drugs.

To know more about cutaneous T-cell lymphoma treatment options, visit @New Treatment for Cutaneous T-cell Lymphoma

Cutaneous T-cell Lymphoma Pipeline Therapies and Key Companies

SGX301: Soligenix
Pembrolizumab: Merck
Resminostat: 4SC AG
CD11301: Galderma
EQ101: Equillium

Learn more about the cutaneous T-cell lymphoma therapies in clinical trials @Drugs for CTCL Treatment

Cutaneous T-cell Lymphoma Market Dynamics

Several pharmaceutical companies are working to develop an effective and affordable therapy for CTCL, so an active pipeline will boost the cutaneous T-cell lymphoma market. In addition, the lack of curative treatment also presents an excellent opportunity for companies to develop therapies that will drive the cutaneous T-cell lymphoma market. Moreover, the growing awareness and rising disease prevalence are prominent factors bolstering the cutaneous T-cell lymphoma market.

Furthermore, compared to other indications, CTCL has a favorable prognosis, which aids in preventing treatment-related complications. The disease tends to develop resistance to medications, necessitating the development of a more efficacious drug that will significantly boost the cutaneous T-cell lymphoma market.

However, some factors hinder the growth of the cutaneous T-cell lymphoma market. The undiagnosed, unreported cases and the unawareness about the disease remain the primary aspects that strive for the cutaneous T-cell lymphoma market growth. In addition, the disease progresses and can result in fatal complications, which can hinder the cutaneous T-cell lymphoma market.

Moreover, despite genetic advances, the molecular mechanisms underlying disease remain unknown. As the disease is rare and heterogeneous, designing and conducting clinical trials is difficult, which further hampers the cutaneous T-cell lymphoma market.

Furthermore, there are currently several competitors in the drug development space working on various classes of therapeutics. As a result, in order to make a cutaneous T-cell lymphoma market impact, therapy should stand out in terms of cost, efficacy, and other relevant parameters.

Scope of the Cutaneous T-cell Lymphoma Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Cutaneous T-cell Lymphoma Companies: Pfizer, Eisai, Citius Pharmaceuticals, Bristol Myers Squibb, Merck, Kyowa Kirin, Medivir, Wellness Pharma, Seagen, Soligenix, 4SC AG, Galderma, Equillium, and others
Key Cutaneous T-cell Lymphoma Therapies: SGX301, Pembrolizumab, Resminostat, CD11301, EQ101, and others
Therapeutic Assessment: Cutaneous T-cell Lymphoma current marketed and emerging therapies
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Cutaneous T-cell Lymphoma Market Access and Reimbursement

Discover more about drugs for cutaneous T-cell lymphoma in development @CTCL Clinical Trials

Table of Contents

1	Key Insights
2	Report Introduction
3	Executive Summary
4	Key Events
5	SWOT Analysis
6	Epidemiology and Market Methodology
7	CTCL Market Overview at a Glance
7.1	Market Share (%) Distribution by Therapies in 2021
7.2	Market Share (%) Distribution by Therapies in 2032
8	Disease Background and Overview
8.1	Introduction
8.2	Classification
8.3	Symptoms
8.4	Etiopathogenesis
8.5	Genomic Landscape of SS/MF
8.6	Biomarkers
8.7	Diagnosis
8.8	Staging and Assessment
9	Treatment and Management of CTCL
10	Treatment Guidelines
11	Epidemiology and Patient Population of CTCL in the 7MM
11.1	Key Findings
11.1.1	Assumptions and Rationale
11.1.1.1	United States
11.1.2.1	The EU5
11.1.3.3	Japan
11.2	Total Incident Population of CTCL in the 7MM
11.3	The United States
11.3.1	Total Incident Population of CTCL in the United States
11.3.2	Type-specific Cases of CTCL in the United States
11.3.3	Subtype-specific Cases of MF in the United States
11.3.4	Gender-specific CTCL cases in the United States
11.3.5	Stage-specific Cases of CTCL in the United States
11.3.6	Treatment-eligible Incident Population in Early-and Advanced-stages in the United States
11.4	The EU5
11.4.1	Total Incident Population of CTCL in the EU5
11.4.2	Type-specific Cases of CTCL in the EU5
11.4.3	Subtype-specific Cases of MF in the EU5
11.4.4	Gender-specific CTCL Cases in the EU5
11.4.5	Stage-specific Cases of CTCL in the EU5
11.4.6	Treatment-eligible Incident Population in Early-and Advanced-stages in the EU5
11.5	Japan
11.5.1	Total Incident Population of CTCL in Japan
11.5.2	Type-specific Cases of CTCL in Japan
11.5.3	Subtype-specific Cases of MF in Japan
11.5.4	Gender-specific CTCL cases in Japan
11.5.5	Stage-specific Cases of CTCL in Japan
11.5.6	Treatment-eligible Incident Population in Early-and Advanced-stages in Japan
12	Patient Journey
13	Key Endpoints in CTCL
14	Marketed Drugs
14.1	Key Competitors
15	Emerging Drugs
15.1	Key Competitors
16	CTCL: 7MM Market Analysis
16.1	Key Findings
16.2	Market Outlook
16.3	Attribute Analysis
16.4	Key Market Forecast Assumptions
16.5	Total Market Size of CTCL in the 7MM
16.6	The United States Market Size
16.6.1	Total Market Size of CTCL in the United States
16.6.2	Market Size of Early-stage CTCL by Therapies in First Line in the United States
16.6.3	Market Size of Early-stage CTCL by Therapies in Second Line in the United States
16.6.4	Market Size of Advanced-stage CTCL by Therapies in First Line in the United States
16.6.5	Market Size of Advanced-stage CTCL by Therapies in Second Line in the United States
16.7	The EU-5 Market Size
16.7.1	Total Market size of CTCL in the EU5
16.7.2	Market Size of Early-stage CTCL by Therapies in First Line in the EU5
16.7.3	Market Size of Early-stage CTCL by Therapies in Second Line in the EU5
16.7.4	Market Size of Advanced-stage CTCL by Therapies in First Line in the EU5
16.7.5	Market Size of Advanced-stage CTCL by Therapies in Second Line in the EU5
16.8	Japan
16.8.1	Total Market size of CTCL in Japan
16.8.2	Market Size of Early-stage CTCL by Therapies in First Line in Japan
16.8.3	Market Size of Early-stage CTCL by Therapies in Second Line in Japan
16.8.4	Market Size of Advanced-stage CTCL by Therapies in First Line in Japan
16.8.5	Market Size of Advanced-stage CTCL by Therapies in Second Line in Japan
17	Unmet Needs
18	Market Access and Reimbursement
18.1	US
18.2	Europe
18.3	Japan
19	Appendix
19.1	Bibliography
19.2	Report Methodology
20	DelveInsight Capabilities
21	Disclaimer
22	About DelveInsight

Get in touch with our Business executive @Healthcare Due Diligence Services

Cutaneous T-cell Lymphoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of cutaneous T-cell lymphoma, historical and forecasted epidemiology, as well as the cutaneous T-cell lymphoma epidemiology trends.

Cutaneous T-cell Lymphoma Pipeline

Cutaneous T-cell Lymphoma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key cutaneous T-cell lymphoma companies, including Wellness Pharma, Seagen, Soligenix, 4SC AG, among others.

Follicular Lymphoma Market

Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key follicular lymphoma companies, including Merck, Genentech, Novartis, Janssen, among others.

Follicular Lymphoma Pipeline

Follicular Lymphoma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key follicular lymphoma companies, including Merck, Genentech, Novartis, Janssen, among others.

Hodgkin Lymphoma Market

Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key Hodgkin lymphoma companies, including 4SC, ACD Therapeutics, TG Therapeutics, among others.

Hodgkin Lymphoma Pipeline

Hodgkin Lymphoma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key Hodgkin lymphoma companies, including 4SC, ACD Therapeutics, TG Therapeutics, among others.

Other Trending Reports

Related Healthcare Blogs

Cutaneous T-cell Lymphoma Market Scenario

Follicular Lymphoma Treatment Market

Follicular Lymphoma Pipeline Landscape

CAR T-cell Therapy for Non-Hodgkin Lymphoma

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Contact Us

Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP